University of Leipzig
uni-leipzig.deTotal trials
147
Active
30
Phase 3
10
Total enrollment
1,054,901
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 7 of 7 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Photosensitizer | — | — | — | — | — | 1 | |
| CO2 | — | — | — | — | — | 1 | |
| Iodinated Contrast Media | — | — | — | — | — | 1 | |
| NORTASE® | — | — | — | — | — | 1 | |
| Luspatercept | — | — | — | — | — | 1 | |
| KEYTRUDA® | — | — | — | — | — | 1 | |
| VEN+AZA-5 | — | — | — | — | — | 1 |
Next readouts
- 2025-11-16
- 2026-07-31
- 2027-06
- 2028-02
- 2028-04
- 2028-12
Top conditions
- Obesity6
- Myocardial Infarction6
- Atrial Fibrillation5
- Coronary Artery Disease4
- Myelodysplastic Syndromes4
- Heart Failure4
- Impaired Glucose Tolerance3
- Cardiac Arrest3
Frequently asked questions about University of Leipzig
- How many clinical trials does University of Leipzig have on ClinicalTrials.gov?
- University of Leipzig is listed as the lead sponsor on 147 clinical trials in ClinicalTrials.gov, 30 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Leipzig's trials are in Phase 3?
- 10 of University of Leipzig's trials are in Phase 3, spread across 7 active drug programs.
- What therapeutic areas does University of Leipzig focus on?
- University of Leipzig's most-studied conditions on ClinicalTrials.gov are Obesity, Myocardial Infarction, Atrial Fibrillation, Coronary Artery Disease, Myelodysplastic Syndromes.
- When are University of Leipzig's next clinical trial readouts?
- University of Leipzig has 6 upcoming primary-completion readouts tracked here; the soonest is “Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy”, expected around 2025-11-16.